Estradiol oral - Theramex SAM

Drug Profile

Estradiol oral - Theramex SAM

Alternative Names: Estreva oral; TX 13323

Latest Information Update: 06 Jan 2011

Price : $50

At a glance

  • Originator Theramex SAM
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Jan 2011 Theramex SAM has been acquired by Teva Pharmaceutical Industries
  • 20 Dec 1999 Theramex SAM acquired by Merck KGaA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top